All In Biotech

Drug Trial Radar · NCT07914933

The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary Thromboendarterectomy

The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary Thromboendarterectomy: a Single-center Pilot Prospective Randomized Placebo-controlled Double-blind Clinical Trial

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Apr 29, 2025

Primary completion

Nov 2027

Study completion Dec 2027

Sponsor

Sponsor type
Research network
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A single-center pilot prospective randomized placebo-controlled double-blind clinical trial. Study objective - to investigate the efficacy and safety of levosimendan in patients in the perioperative period following pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension (CTEPH). Research Objectives: 1. To assess the impact of levosimendan administration on pulmonary artery pressure during the perioperative period in patients who have undergone pulmonary endarterectomy for CTEPH. 2. To evaluate the effect of levosimendan administration on right ventricular function parameters during the perioperative period in patients after pulmonary endarterectomy for CTEPH. 3. To determine the influence of levosimendan on the need for inotropic and vasopressor support (VIS) during the perioperative period in patients following pulmonary endarterectomy for CTEPH. 4. To examine the effect of levosimendan on the clinical course and complications during the postoperative period in patients after pulmonary endarterectomy for CTEPH. 5. To evaluate the cardioprotective effect of levosimendan in patients following pulmonary endarterectomy for CTEPH. 6. To assess the impact of levosimendan on in-hospital mortality in patients after pulmonary endarterectomy for CTEPH.

Conditions

  • LEVOSIMENDAN
  • PULMONARY THROMBOENDARTERECTOMY
  • Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
  • Pulmonary Hypertension

Interventions

  • Infusion of levosimendanDrug

    Infusion of levosimendan will be initiated after the induction of anesthesia, discontinued at the onset of patient cooling, and resumed at the time of rewarming at 34°C. The drug will be administered using an infusion pump as a continuous infusion at a rate of 0.1 mcg/kg/min. The duration of the drug infusion will be up to 48 hours. Preoperative management will be conducted according to the patients' primary and concomitant diseases.

  • Placebo infusion "Soluvit"Drug

    Patients in the placebo group will receive an equivalent amount of a colored solution of Soluvit.Soluvit (ATC B05XC; a yellow vitamin mixture indistinguishable from the investigational drug, levosimendan). Preoperative management will be conducted according to the patients' primary and concomitant diseases.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean pulmonary artery pressure (mPAP)Time frame: 24 hours at the end of surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Meshalkin Research Institute of Pathology of Circulation

    Novosibirsk, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.